103 related articles for article (PubMed ID: 23369219)
1. Bifunctional bisphosphonates for delivering PTH (1-34) to bone mineral with enhanced bioactivity.
Yewle JN; Puleo DA; Bachas LG
Biomaterials; 2013 Apr; 34(12):3141-9. PubMed ID: 23369219
[TBL] [Abstract][Full Text] [Related]
2. Oriented immobilization of proteins on hydroxyapatite surface using bifunctional bisphosphonates as linkers.
Yewle JN; Wei Y; Puleo DA; Daunert S; Bachas LG
Biomacromolecules; 2012 Jun; 13(6):1742-9. PubMed ID: 22559170
[TBL] [Abstract][Full Text] [Related]
3. Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.
Yewle JN; Puleo DA; Bachas LG
Bioconjug Chem; 2011 Dec; 22(12):2496-506. PubMed ID: 22073906
[TBL] [Abstract][Full Text] [Related]
4. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment with intermittent low-dose human parathyroid hormone (1-34) and bisphosphonate enhances large-size skeletal reconstruction by vascularized bone transplantation.
Hashimoto T; Shigetomi M; Ohno T; Matsunaga T; Muramatsu K; Tanaka H; Sugiyama T; Taguchi T
Calcif Tissue Int; 2007 Sep; 81(3):232-9. PubMed ID: 17674071
[TBL] [Abstract][Full Text] [Related]
6. Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.
Shao Y; Hernandez-Buquer S; Childress P; Stayrook KR; Alvarez MB; Davis H; Plotkin LI; He Y; Condon KW; Burr DB; Warden SJ; Robling AG; Yang FC; Wek RC; Allen MR; Bidwell JP
Endocrinology; 2017 Sep; 158(9):2722-2740. PubMed ID: 28637206
[TBL] [Abstract][Full Text] [Related]
7. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice.
Ponnapakkam T; Katikaneni R; Miller E; Ponnapakkam A; Hirofumi S; Miyata S; Suva LJ; Sakon J; Matsushita O; Gensure RC
Calcif Tissue Int; 2011 Jun; 88(6):511-20. PubMed ID: 21512758
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3', 5'-cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells.
Nakao Y; Koike T; Ohta Y; Manaka T; Imai Y; Takaoka K
Bone; 2009 May; 44(5):872-7. PubMed ID: 19442611
[TBL] [Abstract][Full Text] [Related]
9. Treating osteoporosis by targeting parathyroid hormone to bone.
Ponnapakkam T; Katikaneni R; Sakon J; Stratford R; Gensure RC
Drug Discov Today; 2014 Mar; 19(3):204-8. PubMed ID: 23932952
[TBL] [Abstract][Full Text] [Related]
10. Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy.
Arrington SA; Fisher ER; Willick GE; Mann KA; Allen MJ
Calcif Tissue Int; 2010 Sep; 87(3):263-72. PubMed ID: 20563797
[TBL] [Abstract][Full Text] [Related]
11. [Combination therapy for osteoporosis].
Kishimoto H
Nihon Rinsho; 2009 May; 67(5):975-9. PubMed ID: 19432119
[TBL] [Abstract][Full Text] [Related]
12. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
Shen V; Birchman R; Wu DD; Lindsay R
J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
[TBL] [Abstract][Full Text] [Related]
13. Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate.
Cheng PT; Chan C; Müller K
J Bone Miner Res; 1995 Jan; 10(1):119-26. PubMed ID: 7747618
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair.
Sloan AV; Martin JR; Li S; Li J
Bone; 2010 Aug; 47(2):235-40. PubMed ID: 20580684
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate conjugation to proteins as a means to impart bone affinity.
Uludag H; Kousinioris N; Gao T; Kantoci D
Biotechnol Prog; 2000; 16(2):258-67. PubMed ID: 10753453
[TBL] [Abstract][Full Text] [Related]
16. [Morphological analysis of bone dynamics and metabolic bone disease. Effects of parathyroid hormone on bone tissue].
Miyakoshi N
Clin Calcium; 2011 Apr; 21(4):575-81. PubMed ID: 21447925
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.
Iwasaki-Ishizuka Y; Yamato H; Nii-Kono T; Kurokawa K; Fukagawa M
Nephrol Dial Transplant; 2005 Sep; 20(9):1904-11. PubMed ID: 15985520
[TBL] [Abstract][Full Text] [Related]
18. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment.
Oxlund H; Ortoft G; Thomsen JS; Danielsen CC; Ejersted C; Andreassen TT
Bone; 2006 Aug; 39(2):244-52. PubMed ID: 16503210
[TBL] [Abstract][Full Text] [Related]
19. The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat.
Campbell GM; Bernhardt R; Scharnweber D; Boyd SK
Bone; 2011 Aug; 49(2):225-32. PubMed ID: 21515436
[TBL] [Abstract][Full Text] [Related]
20. Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment.
Kim CH; Takai E; Zhou H; von Stechow D; Müller R; Dempster DW; Guo XE
J Bone Miner Res; 2003 Dec; 18(12):2116-25. PubMed ID: 14672346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
